New England Journal of Medicine MARCH 05, 2020

Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

Conradie F, Diacon AH, Ngubane N, et al.

Bottom Line

The Nix-TB study demonstrated that a 6-month, all-oral regimen of bedaquiline, pretomanid, and linezolid (BPaL) achieved a 90% favorable treatment outcome in patients with highly drug-resistant tuberculosis, despite significant adverse events associated with linezolid.

Key Findings

1. The primary outcome of a favorable clinical and bacteriologic status at 6 months after the end of treatment was achieved in 98 of 109 patients (90%; 95% CI, 83-95%).

2. Adverse events were frequent, with 81% of patients experiencing peripheral neuropathy and 48% experiencing myelosuppression, often requiring linezolid dose reductions or temporary treatment interruptions.

3. Unfavorable outcomes were reported in 11 patients (10%), including 6 deaths during treatment, 2 relapses, 1 loss to follow-up, 1 withdrawal, and 1 death during follow-up.

Study Design

Design

Single-arm, Phase 3 trial

Open-Label

Sample

109

Patients

Duration

6 mo

Median

Setting

Multicenter, South Africa

Population Patients aged 14 years and older with extensively drug-resistant (XDR) tuberculosis, or treatment-intolerant or non-responsive multidrug-resistant (MDR) tuberculosis.

Intervention Oral regimen of bedaquiline (400 mg daily for 2 weeks, then 200 mg three times weekly), pretomanid (200 mg daily), and linezolid (starting dose of 1200 mg daily, with dose reductions/interruptions allowed for toxicity) for 26 weeks.

Comparator None (single-arm study)

Outcome Incidence of favorable outcome at 6 months after the end of treatment, defined as the resolution of clinical TB disease and negative culture status.

Study Limitations

• The study was an open-label, single-arm trial, lacking a randomized control group for direct comparative efficacy.

• The sample size was limited to 109 participants, which may constrain the generalizability of safety findings across diverse patient populations.

• High incidence of linezolid-related toxicity necessitated frequent dose adjustments, complicating the interpretation of the specific dosage required for maintaining efficacy while minimizing adverse effects.

Clinical Significance

The BPaL regimen provides a critical, shorter, all-oral therapeutic option for XDR-TB and treatment-intolerant/non-responsive MDR-TB, significantly improving upon historical success rates which were often below 20-30% for these patient groups.

Historical Context

Historically, extensively drug-resistant tuberculosis (XDR-TB) was associated with extremely poor prognosis, often requiring prolonged regimens (18-24 months) involving toxic injectable agents. The Nix-TB trial was pivotal in validating a shorter, all-oral combination therapy (BPaL), fundamentally changing treatment paradigms and leading to the FDA approval of pretomanid in 2019.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What are the distinct mechanisms of action for each component of the BPaL regimen (bedaquiline, pretomanid, and linezolid), and how does this combination overcome traditional mechanisms of multidrug resistance in M. tuberculosis?

Key Response

Bedaquiline inhibits mycobacterial ATP synthase, a novel target; pretomanid is a nitroimidazole that inhibits mycolic acid biosynthesis and acts as a respiratory poison under anaerobic conditions; and linezolid inhibits protein synthesis by binding to the 23S rRNA of the 50S subunit. Using three drugs with unique targets reduces the probability of cross-resistance and allows the regimen to target both actively replicating and dormant (persister) bacilli, which is the foundational logic behind the shortened 6-month treatment duration.

Resident

In a patient undergoing the BPaL regimen, which specific clinical and laboratory parameters must be monitored most aggressively to mitigate the primary toxicities identified in the Nix-TB trial?

Key Response

The Nix-TB trial identified significant linezolid-associated toxicities: myelosuppression (anemia, neutropenia, thrombocytopenia) and peripheral neuropathy. Residents must monitor weekly or bi-weekly CBCs and perform regular neurological exams. Additionally, bedaquiline's potential for QTc prolongation requires baseline and periodic ECG monitoring, especially if the patient is on other QTc-prolonging agents.

Fellow

Given that Nix-TB allowed for linezolid dose reductions and interruptions due to toxicity, how do these clinical adjustments complicate the interpretation of the 'minimal effective dose' required to maintain a 90% success rate without selecting for resistance?

Key Response

In Nix-TB, only 16% of patients completed the full 1200 mg dose of linezolid without interruption. This suggests that the high efficacy may be achievable at lower cumulative exposures. However, from a subspecialty perspective, frequent interruptions raise the risk of functional monotherapy (if bedaquiline or pretomanid levels fluctuate), potentially leading to acquired resistance. This nuance drove subsequent trials like ZeNix to formally investigate 600 mg vs 1200 mg starting doses.

Attending

The Nix-TB study reported a 90% favorable outcome in XDR-TB, a disease with historically dismal survival. How should this 'microbiological success' be balanced against the 81% incidence of peripheral neuropathy in shared decision-making with patients?

Key Response

This question shifts the focus from survival to quality of life. While a 90% cure rate is practice-changing, the high rate of potentially permanent nerve damage requires clinicians to move beyond a 'cure at all costs' mentality. Attending-level practice involves counseling patients on the trade-off between a 6-month intensive oral regimen with high toxicity versus longer, less toxic (but less effective) historical regimens.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

Critique the use of a single-arm, non-randomized study design in Nix-TB. To what extent do historical controls from the pre-bedaquiline era overestimate the treatment effect of the BPaL regimen in contemporary settings?

Key Response

Nix-TB compared its results to historical XDR-TB cohorts where success rates were often below 20-40%. However, historical controls are prone to selection bias and changes in supportive care. A PhD-level critique would highlight that without a concurrent control group, it is difficult to statistically isolate the specific contribution of pretomanid from the known high efficacy of bedaquiline and linezolid when used together.

Journal Editor

As a reviewer, how would you address the potential for 'healthy survivor bias' in the Nix-TB study, given that the primary endpoint was measured 6 months after the completion of a high-toxicity treatment phase?

Key Response

A seasoned editor would flag that patients who survived the initial toxic phase of linezolid treatment to reach the 6-month post-treatment follow-up might not represent the entire intention-to-treat population. The editor would look for rigorous handling of loss-to-follow-up and deaths, ensuring that 'favorable outcome' definitions are not artificially inflated by excluding those who discontinued the drug early due to adverse events.

Guideline Committee

Nix-TB provided the evidence for WHO to recommend BPaL under 'operational research' conditions. What specific evidence gaps remain that prevent BPaL from becoming the universal 'Strong Recommendation' for all MDR-TB cases regardless of resistance profile?

Key Response

Current WHO guidelines (e.g., 2020 updates) transitioned toward all-oral regimens, but BPaL was initially restricted due to concerns over linezolid toxicity and the need for drug susceptibility testing (DST). To move to a 'Strong Recommendation,' the committee needs data on the regimen's performance in children, pregnant women, and patients with pre-existing linezolid resistance, as well as more evidence on the optimal (safer) linezolid dosing schedule (e.g., from the ZeNix trial).

Clinical Landscape

Noteworthy Related Trials

2020

Nix-TB Trial

n = 109 · NEJM

Tested

Bedaquiline, pretomanid, and linezolid (BPaL)

Population

Patients with XDR-TB, treatment-intolerant, or nonresponsive MDR-TB

Comparator

None (single-arm study)

Endpoint

Favorable outcome at 6 months after the end of treatment

Key result: 90% of participants had a favorable outcome, demonstrating the efficacy of the BPaL regimen.

2021

TB-PRACTECAL Trial

n = 552 · NEJM

Tested

Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM)

Population

Patients with bacteriologically confirmed MDR-TB or XDR-TB

Comparator

Standard of care (WHO-recommended MDR-TB treatment)

Endpoint

Composite of death, treatment failure, treatment discontinuation, or recurrence at 72 weeks

Key result: The BPaLM regimen was superior to the standard of care with significantly higher success rates and fewer adverse events.

2022

ZeNix Trial

n = 181 · NEJM

Tested

Bedaquiline, pretomanid, and linezolid (BPaL) with varying linezolid doses/durations

Population

Patients with pulmonary XDR-TB, pre-XDR-TB, or treatment-intolerant/nonresponsive MDR-TB

Comparator

Different linezolid dosages and durations

Endpoint

Favorable status at 26 weeks after treatment completion

Key result: High rates of favorable outcomes were achieved across all dosage groups, suggesting treatment could be optimized to reduce toxicity.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis